Author: Jane Edwards|| Date Published: August 10, 2016
The International AIDS Vaccine Initiative has received a potential seven-year, $98 million contract from the National Institutes of Health to support the agency™s efforts to develop a vaccine against the disease.
IAVI will work with NIH™s National Institute of Allergy and Infectious Diseases to characterize and produce HIV envelope protein immunogens, IAVI said Tuesday.
NIAID-backed scientists designed such immunogens in order to develop vaccine candidates that work to generate immune response against HIV infection and facilitate the evaluation of such experimental vaccines in human clinical trials.
Mark Feinberg, IAVI president and CEO, said IAVI is pleased to provide product development services to NIAID in support of its AIDS vaccine development initiatives.
IAVI is a two-decade-old nonprofit organization that aims to advance AIDS vaccine research and development programs through collaboration with government agencies, pharmaceutical firms, hospitals and universities in 25 countries.
The Department of State has awarded spots on a multiple-award indefinite-delivery/indefinite-quantity contract with a combined potential value of $10 billion…
Brian Hobbs has been appointed CEO of Clarity Innovations, effective March 2, the company announced Tuesday. He succeeds founder and long-serving CEO Wes…
The Federal Aviation Administration has awarded a potential five-year, $437.4 million contract to ASRC Federal Advanced Research to provide second-level…
The International AIDS Vaccine Initiative has received a potential seven-year, $98 million contract from the National Institutes of Health to support the agency™s efforts to develop a vaccine against the disease.
